The bill would create a White House-led system for guiding federal biotechnology work. It would set up a new office, require a national strategy, improve data and safety planning, and push agencies to make biotech product reviews clearer.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
National Biotechnology Initiative Act of 2025 is a Senate bill in committee. The latest recorded action: Committee on Health, Education, Labor, and Pensions. Hearings held.
Latest action on S. 1387: Committee on Health, Education, Labor, and Pensions. Hearings held.
Who this affects: This bill mainly affects federal agencies, biotech companies, researchers, labs, universities, students, workers, and groups that use biological data. It could change how agencies fund research, review products, share data, train workers, and plan for safety and security. It could also affect companies trying to bring biotech products to market because agencies would have to spell out review steps more clearly.
Why this matters: Biotechnology already affects medicine, food, energy, manufacturing, and national security, but federal work is spread across many agencies. This bill would try to pull that work into one national plan. It could help reduce duplicated work, make product reviews easier to follow, improve safety planning, and strengthen U.S. competition with other countries. The tradeoff is that the bill gives the White House a larger role and leaves many details for agencies to decide later.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
